Hunterase®
Idursulfase beta — an enzyme replacement therapy for metabolic disorders.
Indications
Used for long-term treatment of adults and children from birth (0 months of age) with Hunter syndrome (mucopolysaccharidosis type II).
Dosage form
Concentrate for solution for infusion, 2 mg/1 mL; 3 mL vials.
Age restrictions
From birth.
Dosage regimen
The dose is 0.5 mg/kg body weight once weekly. The medicinal product is administered as an intravenous infusion.
Manufacturing and Registration
Manufacturer: GC Biopharma Corporation, 586 Gwahaeok 2-ro, Ochang-eup, Cheongwon-gu, Cheongju-si, Chungcheongbuk-do, 28119, Republic of Korea
Marketing authorization holder: Nanolek LLC, 123112, Moscow, Presnensky Municipal District, Testovskaya St., 10, premises 1/16. Email: info@nanolek.ru
Authorized organization for receiving consumer complaints: Nanolek LLC, 123112, Moscow, Presnensky Municipal District, Testovskaya St., 10, premises 1/16. Email: info@nanolek.ru